PTP Accounts Production v25.2.0.378 13274033 Board of Directors 1.4.24 31.3.25 31.3.25 false true false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh132740332024-03-31132740332025-03-31132740332024-04-012025-03-31132740332023-03-31132740332023-04-012024-03-31132740332024-03-3113274033ns15:EnglandWales2024-04-012025-03-3113274033ns14:PoundSterling2024-04-012025-03-3113274033ns10:Director12024-04-012025-03-3113274033ns10:PrivateLimitedCompanyLtd2024-04-012025-03-3113274033ns10:SmallEntities2024-04-012025-03-3113274033ns10:AuditExemptWithAccountantsReport2024-04-012025-03-3113274033ns10:SmallCompaniesRegimeForDirectorsReport2024-04-012025-03-3113274033ns10:SmallCompaniesRegimeForAccounts2024-04-012025-03-3113274033ns10:FullAccounts2024-04-012025-03-3113274033ns10:Director22024-04-012025-03-3113274033ns10:RegisteredOffice2024-04-012025-03-3113274033ns5:CurrentFinancialInstruments2025-03-3113274033ns5:CurrentFinancialInstruments2024-03-3113274033ns5:ShareCapital2025-03-3113274033ns5:ShareCapital2024-03-3113274033ns5:RetainedEarningsAccumulatedLosses2025-03-3113274033ns5:RetainedEarningsAccumulatedLosses2024-03-3113274033ns5:PlantMachinery2024-03-3113274033ns5:PlantMachinery2024-04-012025-03-3113274033ns5:PlantMachinery2025-03-3113274033ns5:PlantMachinery2024-03-3113274033ns5:CostValuation2024-03-3113274033ns5:AdditionsToInvestments2025-03-3113274033ns5:DisposalsRepaymentsInvestments2025-03-3113274033ns5:CostValuation2025-03-3113274033ns5:WithinOneYearns5:CurrentFinancialInstruments2025-03-3113274033ns5:WithinOneYearns5:CurrentFinancialInstruments2024-03-3113274033ns5:Non-currentFinancialInstruments2025-03-3113274033ns5:Non-currentFinancialInstruments2024-03-3113274033ns10:Director222024-03-3113274033ns10:Director222023-03-3113274033ns10:Director222024-04-012025-03-3113274033ns10:Director222023-04-012024-03-3113274033ns10:Director222025-03-3113274033ns10:Director222024-03-31
REGISTERED NUMBER: 13274033 (England and Wales)















Unaudited Financial Statements for the Year Ended 31 March 2025

for

Molecular Search Ltd

Molecular Search Ltd (Registered number: 13274033)






Contents of the Financial Statements
for the Year Ended 31 March 2025




Page

Company Information 1

Chartered Accountants' Report 2

Statement of Financial Position 3

Notes to the Financial Statements 5


Molecular Search Ltd

Company Information
for the Year Ended 31 March 2025







DIRECTORS: S L Daniel
R McNally





REGISTERED OFFICE: Endeavour House
78 Stafford Road
Wallington
Surrey
SM6 9AY





REGISTERED NUMBER: 13274033 (England and Wales)





ACCOUNTANTS: PB Partners LLP
Endeavour House
78 Stafford Road
Wallington
Surrey
SM6 9AY

Chartered Accountants' Report to the Board of Directors
on the Unaudited Financial Statements of
Molecular Search Ltd

The following reproduces the text of the report prepared for the directors in respect of the company's annual unaudited financial statements. In accordance with the Companies Act 2006, the company is only required to file a Statement of Financial Position. Readers are cautioned that the Income Statement and certain other primary statements and the Report of the Directors are not required to be filed with the Registrar of Companies.

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of Molecular Search Ltd for the year ended 31 March 2025 which comprise the Income Statement, Statement of Financial Position and the related notes from the company's accounting records and from information and explanations you have given us.

As a practising member firm of the Institute of Chartered Accountants in England and Wales (ICAEW), we are subject to its ethical and other professional requirements which are detailed within the ICAEW's regulations and guidance at http://www.icaew.com/en/membership/regulations-standards-and-guidance.

This report is made solely to the Board of Directors of Molecular Search Ltd, as a body, in accordance with our terms of engagement. Our work has been undertaken solely to prepare for your approval the financial statements of Molecular Search Ltd and state those matters that we have agreed to state to the Board of Directors of Molecular Search Ltd, as a body, in this report in accordance with ICAEW Technical Release 07/16AAF. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Molecular Search Ltd and its Board of Directors, as a body, for our work or for this report.

It is your duty to ensure that Molecular Search Ltd has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and loss of Molecular Search Ltd. You consider that Molecular Search Ltd is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or a review of the financial statements of Molecular Search Ltd. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.






PB Partners LLP
Endeavour House
78 Stafford Road
Wallington
Surrey
SM6 9AY


27 August 2025

Molecular Search Ltd (Registered number: 13274033)

Statement of Financial Position
31 March 2025

2025 2024
Notes £    £    £    £   
FIXED ASSETS
Tangible assets 4 5,827 6,916
Investments 5 11,500 71,052
17,327 77,968

CURRENT ASSETS
Debtors 6 26,893 146,582
Cash at bank 592,947 603,167
619,840 749,749
CREDITORS
Amounts falling due within one year 7 39,008 31,689
NET CURRENT ASSETS 580,832 718,060
TOTAL ASSETS LESS CURRENT
LIABILITIES

598,159

796,028

PROVISIONS FOR LIABILITIES 5,701 -
NET ASSETS 592,458 796,028

CAPITAL AND RESERVES
Called up share capital 102 102
Retained earnings 592,356 795,926
592,458 796,028

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 March 2025.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 March 2025 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

Molecular Search Ltd (Registered number: 13274033)

Statement of Financial Position - continued
31 March 2025


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 27 August 2025 and were signed on its behalf by:





R McNally - Director


Molecular Search Ltd (Registered number: 13274033)

Notes to the Financial Statements
for the Year Ended 31 March 2025

1. STATUTORY INFORMATION

Molecular Search Ltd is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the Pound Sterling (£).


2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off the cost less estimated residual value of each asset over its estimated useful life.

Plant & Machinery 25% straight line

Investments
Fixed Asset investments are shown at cost less provision for impairment. Current asset investments are stated at the lower of cost and net realisable value.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the statement of financial position date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the statement of financial position date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Foreign currencies
Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of transaction.

At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.

Molecular Search Ltd (Registered number: 13274033)

Notes to the Financial Statements - continued
for the Year Ended 31 March 2025

2. ACCOUNTING POLICIES - continued

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 3 (2024 - 4 ) .

4. TANGIBLE FIXED ASSETS
Plant and
machinery
£   
COST
At 1 April 2024 12,794
Additions 2,439
At 31 March 2025 15,233
DEPRECIATION
At 1 April 2024 5,878
Charge for year 3,528
At 31 March 2025 9,406
NET BOOK VALUE
At 31 March 2025 5,827
At 31 March 2024 6,916

5. FIXED ASSET INVESTMENTS
Other
investments
£   
COST
At 1 April 2024 71,052
Additions 11,500
Disposals (71,052 )
At 31 March 2025 11,500
NET BOOK VALUE
At 31 March 2025 11,500
At 31 March 2024 71,052

Molecular Search Ltd (Registered number: 13274033)

Notes to the Financial Statements - continued
for the Year Ended 31 March 2025

6. DEBTORS
2025 2024
£    £   
Amounts falling due within one year:
Trade debtors 20,031 117,238
Directors' current accounts - 10,171
Corporation tax 4,713 -
Social security and other taxes - 5,344
Prepayments 2,149 6,100
26,893 138,853

Amounts falling due after more than one year:
Other debtors - 7,729

Aggregate amounts 26,893 146,582

7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2025 2024
£    £   
Trade creditors 1,531 -
Corporation tax - 4,731
Social security and other taxes 1,888 6,923
Other creditors 174 19,685
Directors' current accounts 33,414 349
Accruals and deferred income 2,001 1
39,008 31,689

8. DIRECTORS' ADVANCES, CREDITS AND GUARANTEES

The following advances and credits to a director subsisted during the years ended 31 March 2025 and 31 March 2024:

2025 2024
£    £   
S L Daniel
Balance outstanding at start of year 10,171 (2,249 )
Amounts advanced 29,000 12,420
Amounts repaid (39,171 ) -
Amounts written off - -
Amounts waived - -
Balance outstanding at end of year - 10,171

9. ULTIMATE CONTROLLING PARTY

The company is controlled by the directors.